Want to see SE:XSPRAY full AI Analyst Report?
XSPRAY Stock Chart & Stats
kr10.74
kr0.28(1.83%)
At close: 4:00 PM EDT
kr10.74
kr0.28(1.83%)
Day’s Range― - ―
52-Week Rangekr9.14 - kr62.33
Previous CloseN/A
Volume28.64K
Average Volume (3M)163.60K
Market Cap
kr442.87M
Enterprise Valuekr645.43
Total Cash (Recent Filing)kr179.91M
Total Debt (Recent Filing)kr147.30M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Nov 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.86
Shares Outstanding47,416,573
10 Day Avg. Volume50,739
30 Day Avg. Volume163,596
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio-5.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.2
Revenue Forecast (FY)kr95.00M
Bulls Say, Bears Say
Bulls Say
Moderate LeverageSubstantial equity relative to debt provides a comparatively solid capital base for a development-stage biotechnology company. Moderate leverage can preserve financial flexibility for advancing candidates and negotiating partnerships, although ongoing losses remain an important constraint on that strength.
Improving Net Loss TrendThe reduction in net losses from the 2024 trough indicates some improvement in profitability, even though the company remains deeply unprofitable. If sustained, lower losses could extend financial runway and reduce the funding burden while products progress toward commercialization.
HyNap Formulation PlatformHyNap gives Xspray a technology-led model focused on improving established medicines rather than discovering entirely new compounds. Potential bioavailability and food-effect advantages may support differentiated products, licensing opportunities, and partner-led commercialization across specialty markets.
Bears Say
No Revenue And Persistent LossesThe absence of reported revenue means the business has not yet demonstrated commercial monetization, while persistent losses show that development costs continue to exceed operating income. Until approvals and product uptake create revenue, earnings visibility and self-funded growth remain limited.
Sustained Cash Burn持续 negative operating and free cash flow indicates that core activities are consuming cash rather than funding themselves. This places continued emphasis on financing, partnerships, or future commercialization proceeds and could constrain development priorities if external capital becomes less available.
Rising Leverage And Negative ROEAlthough current leverage remains moderate, its material increase from earlier years reduces the balance sheet cushion as losses continue. Negative returns on equity show that invested capital is not yet producing earnings, increasing sensitivity to prolonged development timelines and additional funding needs.
Xspray Pharma AB News
XSPRAY FAQ
What was Xspray Pharma AB’s price range in the past 12 months?
Xspray Pharma AB lowest stock price was kr9.14 and its highest was kr62.33 in the past 12 months.
What is Xspray Pharma AB’s market cap?
Xspray Pharma AB’s market cap is kr442.87M.
When is Xspray Pharma AB’s upcoming earnings report date?
Xspray Pharma AB’s upcoming earnings report date is Nov 04, 2026 which is in 45 days.
How were Xspray Pharma AB’s earnings last quarter?
Xspray Pharma AB released its earnings results on Aug 05, 2026. The company reported -kr0.868 earnings per share for the quarter.
Is Xspray Pharma AB overvalued?
According to Wall Street analysts Xspray Pharma AB’s price is currently Overvalued.
Does Xspray Pharma AB pay dividends?
Xspray Pharma AB does not currently pay dividends.
What is Xspray Pharma AB’s EPS estimate?
Xspray Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xspray Pharma AB have?
Xspray Pharma AB has 47,416,573 shares outstanding.
What happened to Xspray Pharma AB’s price movement after its last earnings report?
Xspray Pharma AB reported an EPS of -kr0.868 in its last earnings report. Following the earnings report the stock price went down -6.988%.
Which hedge fund is a major shareholder of Xspray Pharma AB?
Currently, no hedge funds are holding shares in SE:XSPRAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xspray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical firm based in Solna, Sweden, specializes in developing protein kinase inhibitors for precise cancer treatments. Their current drug pipeline includes HyNap-Nilo, aimed at chronic myeloid leukemia; HyNap-Sora, which targets renal, liver, and several types of thyroid cancer; and HyNap-Dasa, intended for both chronic myeloid leukemia and acute lymphoblastic leukemia. Established in 2003, the company was formerly known as Xspray Microparticles AB until its name change to Xspray Pharma AB (publ) in 2017.
Technical Analysis
Camurus AB
―
Vicore Pharma Holding AB
―
Xbrane Biopharma AB
―
Spago Nanomedical AB
―
Bio-Works Technologies AB
―